This site requires JavaScript to render the code.

Need to know how to enable JavaScript? Go here.

November 2018, QIAGEN launches Self-screens HPV-Risk Assay as the QIAscreen HPV PCR Test

Hilden, Germany, November 28, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAscreen HPV PCR Test, a CE-IVD marked molecular diagnostic test for the detection of 15 recognized high-risk genotypes of human papillomavirus (HPV), the virus considered to be the cause of cervical cancer. The assay includes both screening and genotyping functionality in one assay. QIAscreen is a new addition to the QIAsymphony product family; an RGQ-based HPV test to support consolidated laboratory market segment

QIAGEN collaborated with Self-screen BV, a biotech spinoff company of VU University Medical Center in Amsterdam, in developing this test. Self-screen is the Legal Manufacturer of the QIAscreen HPV PCR Test. “We are pleased to partner with QIAGEN again to bring another innovative HPV diagnostic application to the market. QIAscreen and QIAsure together will give clinicians the ability to provide women all the critical information necessary to make the best-informed decision for their clinical management,” said Prof. Dr. Chris Meijer, Chief Executive Officer of Self-screen.